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To examine the proteomic background of lymph node metastasis (LNM) in gastric cancer,
we  performed protein expression proﬁling of paired non-tumor, primary tumor, and LNM
tissues. Using a label-free proteomic approach, we generated protein expression proﬁles of
3894  unique proteins and identiﬁed 109 differentially expressed proteins. Functional path-
way  analysis of the differentially expressed proteins showed that members of the beta-3
integrin (ITGB3) pathway were signiﬁcantly enriched. Aberrations of ITGB3 were reported
in  various malignancies; however, ITGB3 in LNM tissues has not been examined to date.
Different level of ITGB3 expression was conﬁrmed in 20 gastric cancer cases by Western
blotting. We analyzed the mRNA levels of the differentially expressed proteins by using a
public mRNA expression database; 38.8% of the proteins examined, including those involved
in  oxidation and reduction, showed correlation between protein and mRNA levels. Proteins
without such correlation included factors related to cell adhesion. Our study suggests a novelranscriptome role  for the integrin pathway in the development of LNM in gastric cancer and indicated
possible beneﬁts of observational transcriptomic analysis for proteomic studies.
©  2014 Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA).
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
most important prognostic factors for gastric cancer, and.  Introductionastric cancer is the fourth most common cancer and the
econd leading cause of cancer-related deaths worldwide
1]. Lymph node metastasis (LNM) is an early event of
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ing of the molecular mechanisms of LNM can lead to a novel
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prognostic indicator or therapeutic approach for the treatment
of gastric cancer.
Metastasis of tumor cells consists of multiple selection
steps. Subpopulations of cancer cells with high metastatic
potential may migrate from the primary site to distant tissues,
where cells adaptive to foreign microenvironments clonally
proliferate in metastatic sites [6]. To elucidate the molecular
mechanisms underlying these multistage events, genome-
wide screening has been performed to identify genetic
differences between the primary tumors and the LNM tis-
sues in gastric cancer [7,8]. These studies have suggested the
existence of complex genetic abnormalities related to gastric
cancer metastasis.
The proteome is a functional translation of the genome.
The genomic aberrations of cancer cells are transcribed to
the transcriptome, translated to the proteome, then deter-
mining cancer phenotypes. In this sense, the proteome is
a functional translation of the genome, directly regulating
tumor behavior. Proteomic studies can generate unique data
about the ﬁnal products of genome information. The pro-
teomic study has been employed to elucidate the mechanisms
underlying LNM development in several types of cancers,
and various intriguing ﬁndings have been reported [9]. There-
fore, the investigations by the proteomic approach will be
important clues to understand the molecular mechanisms
underlying LNM in gastric cancer. These approaches will fur-
ther the understanding of biological mechanisms in gastric
cancer progression and will eventually beneﬁt cancer patients.
In this study, we aimed to elucidate the proteomic back-
ground of LNM in gastric cancer. Protein expression proﬁles
consisting of 3894 unique proteins were generated using
sodium dodecyl sulfate (SDS)-PAGE-based protein separa-
tion followed by LC–MS/MS. Using a label-free quantiﬁcation
method, we  identiﬁed 109 differentially expressed proteins in
the LNM tissues. Functional pathway analysis demonstrated
that proteins involved in the beta-3 integrin (ITGB3) pathway
were signiﬁcantly enriched within LNM, and the expression
pattern of ITGB3 in gastric cancer progression and metastasis
was examined by Western blotting. The application of meta-
transcriptomics revealed the possible trends of proteins with
concordant and discordant expression between proteins and
mRNA.
2.  Material  and  methods
2.1.  Clinical  samples
This study included 20 patients with gastric cancer. Matched
and unmatched pairs of tumors, non-tumor and LNM tis-
sues were used; paired tissues from two cases were used for
proteomic studies, and all samples were used for Western
blotting. The patients underwent surgery at Niigata Univer-
sity Medical and Dental Hospital and the afﬁliated institutions
in Niigata prefecture (Nagaoka Chuo General Hospital, Nan-
bugo General Hospital, Nagaoka Red Cross Hospital, Nippon
Dental University Medical Hospital, Niigata City General Hos-
pital, Tachikawa General Hospital, Shibata Hospital, Saiseikai
Niigata Daini Hospital, Sakamachi Hospital, Kashiwazaki Gen-
eral Hospital and Medical Center). All patients underwent 3 ( 2 0 1 4 ) 183–194
surgical resection in 2010 and had no history of cancer treat-
ments involving systemic therapy. At the time of surgery,
tissue fragments were grossly resected from the primary
tumors, and the matched non-tumor mucosa tissues located
at least 5 cm away from the tumor margins were collected.
All the tissues were immediately snap-frozen in liquid nitro-
gen and stored at −80 ◦C until use. The LNM tissues were
cut into two pieces; one was embedded in OCT compound
(Sakura Finetechnical, Tokyo, Japan) for histological iden-
tiﬁcation of tumor metastasis, and another was used for
proteomic study and Western blotting. By staining frozen sec-
tions with hematoxylin–eosin, we  conﬁrmed that the lymph
node metastatic tissues had at least 50% tumor cells. The
tumors were classiﬁed on the basis of the histological stage,
according to the International Union against Cancer tumor-
node-metastasis (TNM) classiﬁcation, 7th edition [10]. The
clinicopathological data for 20 cases are presented in Table 1.
This study was approved by the Ethical Review Board of the
Niigata University Faculty of Medicine, the afﬁliated institu-
tions of Niigata University Medical and Dental Hospital, and
National Cancer Center. Informed consent was obtained from
all the patients at each institution.
2.2.  Protein  expression  proﬁling
Frozen samples were crushed to powder in liquid nitrogen
with a Multi-beads shocker (Yasui Kikai, Osaka, Japan) and
treated with lysis buffer containing 6 M urea, 2 M thiourea,
3% CHAPS, and 1% Triton X-100. After the mixtures were
centrifuged at 15,000 rpm for 30 min, the supernatants were
recovered and used in subsequent protein expression studies.
Protein expression proﬁles were generated by the
LC–MS/MS method. Sixty micrograms  of each protein sample
was separated on a ready-made 12.5% SDS-PAGE gel (ATTO,
Tokyo, Japan). Each gel lanes were cut into 48 pieces of equal
size by GridCutter (Gel Company, San Francisco, CA) and
subjected to in-gel tryptic digestion as described previously
[11]. Trypsin digests were subjected to liquid chromatography
coupled with analysis with a LTQ-Orbitrap XL mass spectrom-
eter (Thermo Fisher Scientiﬁc, San Jose, CA). Acquired MS and
MS/MS spectra (Thermo raw ﬁles) were analyzed with the
Progenesis LC-MS software, version 3.4 (Nonlinear, Dynamics,
Newcastle, UK). Proﬁle data of MS scans were transformed
to peak lists with respective peak m/z  values, intensities,
abundances (areas under the peaks), and m/z  width. MS/MS
spectra were treated similarly.
After selecting one sample as the reference, the reten-
tion times of all the other samples used in the experiment
were aligned by manually creating three to ﬁve landmarks,
followed by automatic alignment of all retention times to max-
imal overlay of the 2D feature maps. Features with only two
or three charges were included in further analyses. MS/MS
spectra were exported from the Progenesis software as Mas-
cot generic ﬁles (mgf) and were used for peptide identiﬁcation
by searching the SWISS-PROT database (Homo sapiens, 471,472
sequences in the Sprot 57.5.fasta ﬁle) by using the Mascot soft-
ware  (version 2.2; Matrix Science, London, UK). The following
search parameters were used: tolerance of two missed trypsin
cleavages, variable modiﬁcations on the methionine residue
(oxidation, +16 Da), maximum precursor ion mass tolerance
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Table 1 – Clinical and pathological data of the gastric cancer patients who participated in this study.
Case
numbera
Patient
age
Patient
sex
Histological
differentiation
T  statusb N statusb M statusb Number of
metastatic nodes
Lymphatic
invasion
Vascular
invasion
TNM
stageb
1 76 Male WD T4 N3 M1 9 Presence Presence IV
2 65 Male MD T4 N1 M1 2 Presence Presence IV
3 81 Male WD T1 N0 M0 0 Absence Absence I
4 68 Male WD T1 N0 M0 0 Absence Absence I
5 70 Male MD T2 N0 M0 0 Absence Absence I
6 63 Male MD T2 N0 M0 0 Absence Absence I
7 57 Male WD T1 N0 M0 0 Absence Absence I
8 72 Male MD T3 N0 M0 0 Absence Absence II
9 63 Male MD T3 N0 M0 0 Absence Absence II
10 72 Male MD T2 N1 M0 1 Presence Absence II
11 81 Male MD T3 N1 M0 1 Presence Absence II
12 76 Male WD T3 N1 M0 1 Presence Presence II
13 64 Male MD T2 N1 M0 1 Presence Presence II
14 56 Male MD T3 N3 M0 18 Presence Presence III
15 77 Male MD T3 N3 M0 12 Presence Presence III
16 55 Male MD T3 N2 M0 3 Absence Absence III
17 76 Male MD T3 N3 M0 7 Presence Presence III
18 75 Male MD T3 N2 M0 3 Absence Presence III
19 72 Male MD T4 N3 M1 11 Presence Presence IV
20 70 Male WD T4 N3 M1 12 Presence Presence IV
WD, well differentiated; MD, moderately differentiated.
a The samples in case 1 and 2 were used to create the protein expression proﬁles, and those in case 1 to20 were used for Western blotting analysis.
b T status, N status, M status and TNM stage were determined according to the International Union against Cancer tumor-node-metastasis (TNM) classiﬁcation of 7th edition.
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of ±10 ppm, and fragment ion mass tolerance of ±0.8 Da. Pro-
teins with a Mascot score of 34 or more  were considered as
positively identiﬁed. Peptide search results were re-imported
to the Progenesis software.
For protein quantiﬁcation, only nonconﬂicting peptides
(i.e., peptides occurring in only one protein) were selected.
After summing up the abundances of all the peptides allocated
to each protein, the results of 48 fractions were combined in
a total analysis set. All the experiments were performed in
duplicates, and each number represented an average of two
replicates. The processed raw data on protein abundances
were normalized by ﬁxing the mean intensity of each sam-
ple at one and were presented as a scatter plot; the ratios of
mean abundances in two cases between tissue types were cal-
culated using the Expressionist analyst software (GeneData,
Basel, Switzerland). We  deﬁned the different expression as
more  than 2.0-fold difference of the mean protein abundance
between tissue types. Proteins that showed higher expression
in tumor than non-tumor tissues, and also higher expression
in LNM than in the tumor tissues, or proteins that showed
lower expression in tumors than in the non-tumor tissues,
and even lower expression in the LNM tissues were selected
as candidate proteins associated with LNM.
2.3.  Pathway  analysis
Pathway analysis of differentially expressed proteins was
performed using the Cytoscape software [12] with the Reac-
tome functional interaction (FI) plug-in [13]. The Reactome FI
dataset unites interactions from Reactome and those derived
from the pathway databases, including KEGG, BioCye, Pan-
ther, The Cancer Cell Map  (http://cancer.cellmap.org/), and
NCI-PID, with pair-wise interactions gleaned from physical
protein-protein interactions in human and model organisms,
gene coexpression data, protein domain–domain interactions,
protein interactions generated from text mining, and GO
annotations [13]. To investigate the functions of the network
created, pathway enrichment analysis was performed using
the Reactome FI plug-in. Pathways with a false discovery rate
(FDR) < 0.05 were considered to be signiﬁcantly enriched.
2.4.  Western  blotting
Protein samples were separated by SDS-PAGE and blotted
onto a PVDF membrane. Primary antibodies against ITGB3
(1:1000; BD Bioscience, San Jose, CA) and secondary antibod-
ies against mouse IgG (1:2000, GE Healthcare Biosciences,
Uppsala, Sweden) were used, and immunocomplexes were
detected using an enhanced chemiluminescence system (ECL
Prime Western Blotting Detection Reagents; GE Healthcare
Biosciences) and LAS-3000 (Fujiﬁlm, Tokyo, Japan). To nor-
malize the amount of protein loaded in each lane, the same
membranes were stained with Ponceau S. The intensity of
Western Blot signals and the density of the total lanes stained
with Ponceau S were measured using ImageQuant software
(GE Healthcare Biosciences), and the relative intensity was cal-
culated by dividing the intensity of Western Blot signals by the
optical density of the total lanes. 3 ( 2 0 1 4 ) 183–194
2.5.  Gene  expression  analysis
The microarray and clinical and pathological dataset of 89
gastric cancer cases was obtained from the Gene Expression
Omnibus (GEO) database (GSE 4007). This dataset consists of
a total of 44,500 probes corresponding to about 30,300 unique
genes. Gene expression data of 14 cases that included 14 pri-
mary  tumor tissues, 14 corresponding LNM tissues, and 5
matched non-tumor mucosae, were selected for the analy-
sis. To compare protein and mRNA  expression, we  selected
probes corresponding to the differentially expressed 109 genes
identiﬁed in proteomic analysis. We  could obtain the expres-
sion data of 67 genes. We  selected a probe with the highest
expression value when multiple ones exist for the identical
gene. Additional data processing such as normalization was
not performed. Gene expression data were imported to the
Expressionist analyst software (GeneData, Basel, Switzerland),
and mean expression ratios between different tissue types
were calculated. We deﬁned the different expression as more
than 1.0 fold difference of the mean expression value between
the tissue types.
2.6.  Gene  ontology  enrichment  analysis
Gene ontology (GO) enrichment analysis was performed using
DAVID, version 6.7 [14]. Data related to genes with concordant
and discordant mRNA  and protein expression were separately
uploaded to DAVID, and the background was deﬁned as “Homo
sapiens”. Functional annotation charts were created using
“GOTERM BP FAT” (collection of broadest GO terms curated
from GO annotations dataset). Thresholds were changed to
a gene count of two and an EASE score of one (modiﬁed
Fisher exact P-value). The P-value for each GO term reﬂects
enrichment in the frequency of that GO term in the uploaded
gene list, relative to all the genes in the background list.
The GO terms were ﬁltered to include enrichments with
Benjamini–Hochberg corrected P-values less than 0.20.
2.7.  Statistical  analysis
The Kruskal–Wallis test was performed to compare contin-
uous variables in multiple groups by using the SPSS 11.5
statistical package (SPSS, Chicago, IL), and differences with
P < 0.05 were considered statistically signiﬁcant.
3.  Results
An overview of the experiment workﬂow is shown in Fig. 1.
First, we  generated protein expression proﬁles of paired non-
tumor, tumor, and LNM tissues from cases 1 and 2 (Fig. 1,
Table 1). Each protein sample was separated by SDS-PAGE, and
the gel lanes were cut to obtain 48 pieces. Trypsin digests were
extracted from each gel piece, and subjected to LC–MS/MS.
We identiﬁed and quantiﬁed 109,949 unique peptides corre-
sponding to 3894 nonredundant proteins from six samples in
technical duplicates by the Progenesis LC-MS software (Sup-
plementary Tables 1 and 2). To monitor the reproducibility of
the whole process (SDS-PAGE separation, in-gel tryptic diges-
tions, LC–MS/MS, and protein quantiﬁcation), we  generated a
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Fig. 1 – Experimental workﬂow of a label-free proteomics
approach with pathway enrichment and mRNA  expression
meta-analysis. Non-tumor (NT), tumor (T) and lymph node
metastasis (LNM) tissues were  examined. The label-free
quantiﬁcation method quantiﬁed the expression of a total
of 3894 proteins; 109 differentially expressed proteins were
further analyzed for functional interactions and biological
enriched pathways. The beta-3 integrin (ITGB3) pathway
was the most enriched pathway in the functional
interaction network created. The association between
ITGB3 protein expression and gastric cancer progression
was conﬁrmed by Western blotting. Among the 109 genes,
67 were grouped according to similarity between the
protein and mRNA  expression patterns, such as
“Concordant genes” or “Discordant genes”. Gene ontology
analysis showed the enriched functional characteristics in
the each gene groups.
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tcatter plot of technical duplicates from identical samples of
he primary tumor tissue from case 2 (Table 1) and calculated
he Pearson’s correlation coefﬁcient. The scatter plot showed
hat the normalized abundance of 83.7% and 94.5% of the pro-
eins ranged within 2.0–4.0-fold difference, respectively, and ( 2 0 1 4 ) 183–194 187
that the correlation coefﬁcient was 0.92 (Supplementary Fig.
1). These results demonstrated high reproducibility of label-
free protein expression proﬁling.
Supplementary Tables 1 and 2 and Fig. 1 can be found, in
the online version, at doi:10.1016/j.euprot.2014.03.001.
We compare protein expression proﬁles between the
non-tumor, tumor, and LNM tissues in two cases (Case 1 and
2, Table 1). Among the 3894 proteins, 55 proteins showed
signiﬁcantly (>2-fold ratio of means in two cases) higher
expression in tumor than non-tumor tissues and also signif-
icantly higher expression in LNM than in the tumor tissues
(Fig. 2). In contrast, 54 proteins showed signiﬁcantly (<2-fold
ratio of means in two cases) lower expression in tumors
than in the non-tumor tissues, and even signiﬁcantly lower
expression in the LNM tissues (Fig. 3). We  selected the 109
differentially expressed proteins as candidate proteins asso-
ciated with LNM. Details of these proteins are presented in
Supplementary Table 3.
Supplementary Table 3 can be found, in the online version,
at doi:10.1016/j.euprot.2014.03.001.
We studied the functional interactions of these 109 pro-
teins by using Cytoscape with the Reactome FI plug-in. We
found that 11 (10.1%) of the 109 proteins were functionally
linked to each other and that the ITGB3 cell surface inter-
actions pathway was the most signiﬁcantly enriched in the
identiﬁed network of the 11 proteins (FDR < 1.00E-4, Fig. 4A and
Table 2). ITGB3 was identiﬁed and examined in our proteomic
analysis. ITGB3 protein expression in the LNM tissues was
lower than that of the tumor tissues (ratio of means = 3.96),
and that of the tumor tissues was higher than that of the
non-tumor tissues (ratio of means = 1.76) (Fig. 4B). We  vali-
dated the relationship between ITGB3 expression and gastric
cancer progression in 20 cases by Western blotting. ITGB3
expression was found to signiﬁcantly increase with cancer
stage progression but decrease in LNM tissues (Fig. 4C). These
observations conﬁrmed the results of the label-free protein
expression proﬁling.
We analyzed the mRNA  levels for the 109 differentially
expressed proteins by using a public mRNA  expression
database. We selected the GSE4007 dataset in the NCBI Gene
Expression Omnibus (GEO) because it was the only dataset
that included mRNA  expression data obtained from paired
non-tumor tissues, primary tumor tissues, and LNM tissues,
along with sufﬁcient clinical information. From the 109 genes,
the mRNA  expression data for 67 genes were included in the
GSE4007 dataset. Clinical and pathological information and
data on mRNA  expression have been presented in Supplemen-
tary Tables 4 and 5, respectively.
Supplementary Tables 4 and 5 can be found, in the online
version, at doi:10.1016/j.euprot.2014.03.001.
To characterize the genes according to the correlation
between mRNA  and protein expression, we  divided the 67
genes into two groups: 26 genes (38.8%) that showed the same
protein and mRNA  expression patterns were grouped into
“Concordant genes” (Table 3), whereas 41 genes that showed
different patterns were grouped into “Discordant genes”. We
analyzed the enriched GO terms in each group by using DAVID,
version 6.7. GO terms related to oxidation, reduction, or hor-
mone metabolism were enriched in the group of “Concordant
genes”, while those involved in phagocytosis or cell adhesion
188  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 183–194
Fig. 2 – Fifty-ﬁve signiﬁcantly upregulated proteins identiﬁed by a label-free quantiﬁcation method. The protein abundance
in each case was z-transformed across all six samples and has been presented in a heatmap format. Tissue types are
marked as non-tumor (NT), tumor (T), and lymph node metastasis (LNM). Case numbers correspond to those in Table 1 and
Fig. 4. Refer to Supplementary Table 3 for the gene description and values of the ratio of means.were over-represented in the “Discordant genes” group (Fig. 5
and Supplementary Table 6).
Supplementary Table 6 can be found, in the online version,
at doi:10.1016/j.euprot.2014.03.001.
4.  Discussion
LNM is one of the most important prognostic factors in gas-
tric cancer, and investigation of the molecular background of
LNM formation may lead to novel therapeutic modalities [4].
Metastasis has been assumed to occur through clonal genomic
and epigenetic evolution [5]. Molecular mechanisms related to
tumor metastasis are upregulated in metastatic tumor cells
compared to primary tumors, and exploring differences inthe molecular background of primary tumors and LNM tis-
sues may be the most direct and credible way to elucidate the
molecular mechanisms underlying the metastasis process.
We employed SDS-PAGE-based size fractionation before
mass spectrometry analysis. Pre-fractionation of proteins by
SDS-PAGE has signiﬁcant advantages over other separation
techniques in that it detects a greater number of proteins
and is widely used to characterize protein complexes in can-
cer proteomic studies [15–17]. Gel-based size fractionation for
the identiﬁcation of proteins is superior to separation by liq-
uid chromatography as a pre-fractionation method [18]. Jafari
et al. compared gel-based protein-separation techniques,
including SDS-PAGE, isoelectric focusing with immobilized
pH gradient gel strips (IEF-IPG), and two-dimensional PAGE
(2D-PAGE), on the basis of their ability to serve as a
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Fig. 3 – Fifty-four signiﬁcantly downregulated proteins identiﬁed by a label-free quantiﬁcation method. The protein
abundance of each gene was z-transformed across all 6 samples and has been presented in a heatmap format. The tissue
types are marked as shown in Fig. 2. Case numbers correspond to those in Table 1 and Fig. 4. Refer to Supplementary Table
3 for the gene description and values of the ratio of means.
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Sractionation technique for MS  analysis of a complex protein
ample [19]. They reported that SDS-PAGE yielded the highest
umber of identiﬁable proteins.
In addition, we  quantiﬁed the identiﬁed proteins by
 label-free method with the Progenesis LC-MS software.
abel-free quantiﬁcation is widely used because it is a simple
echnique that allows simultaneous identiﬁcation and quan-
iﬁcation of proteins. Alternatively, isotopic labeling methods
uch as ICAT [20], iTRAQ [21], and SILAC [22] are also used for
S-based protein quantiﬁcation; these isotopic labeling meth-
ds allow for the comparison of multiple samples in a single
C–MS/MS run, thereby providing increased accuracy, preci-
ion, and reproducibility [23]. However, such experiments are
omplicated because of the additional labeling reactions, and
ILAC is available only in tissue culture systems. A label-freemethod based on Progenesis LC-MS can quantify and iden-
tify thousands of proteins from complex samples with a
simple technique and high reproducibility. Progenesis LC-MS
aligns the ion chromatograms to compensate for variations in
retention times among multiple samples before quantiﬁcation
based on ion intensities. It has been reported that analy-
sis of retention time alignment shows similar quantiﬁcation
precision and reproducibility but higher identiﬁcation capac-
ity than isotope labeling methods such as SILAC [24]. In this
study, we identiﬁed and quantiﬁed 3894 non-redundant pro-
teins from complex clinical samples with high reproducibility
(Supplementary Fig. 1) and then employed a label-free quan-
tiﬁcation method for the proteomic studies.
The development of tumor invasion and metastasis is a
very complicated and continuous process with multi steps.
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Fig. 4 – Beta-3 integrin (ITGB3) pathway and association of
the ITGB3 protein expression with progression of gastric
cancer. Case numbers corresponded to those in Table 1.
Functional interaction network analysis by Cytoscape with
the Reactome FI plug-in is demonstrated (A). The ITGB3
protein expression level quantiﬁed by a label-free method
(B). ITGB3 protein expression level was z-transformed
across all six samples examined and was represented as a
heat-map format and line chart. ITGB3 protein expression
in 20 gastric cancer cases, evaluated by Western blotting (C).
Investigation of the molecular background of tumor metas-
tasis through “omics” studies revealed that multiple genes
aberrations were contributed to the tumor metastasis [7,8].
Therefore, we  tried to examine the overall features of the
expressed proteins, and identiﬁed 109 aberrantly expressed
proteins. Next, we  identiﬁed the ITGB3 pathway as the most
enriched protein interaction network thorough the pathway
enrichment analysis in the 109 proteins (Fig. 4A). In addition,
we monitored the ITGB3 protein expression using the cre-
ated protein expression proﬁle. Integrins are heterodimeric
cell surface glycoproteins with alpha and beta subunits. ITGB3
expression is mainly associated with the migration and inva-
sion of tumor cells [25], and overexpression of ITGB3 is related
to the metastatic potential of melanoma [26], breast cancer
[27], colorectal cancer [28], and bone metastasis in breast
cancer [29]. However, in ovarian cancer, ITGB3 reduces the 3 ( 2 0 1 4 ) 183–194
metastatic potential of tumor cells [30–32]. In hepatocellular
carcinoma cells, ITGB3 has been shown to have a proapoptotic
function, and downregulation of ITGB3 is related to aggres-
sive tumor growth [33]. Therefore, the association of ITGB3
expression with tumor metastasis and progression depends
on the cancer type. In the current study, ITGB3 expression was
increased as cancer stage advanced, thereby linking it to gas-
tric cancer progression. These observations are supported by
previous ﬁndings [34]. However, downregulation of ITGB3 in
the LNM tissues has not been reported until our study. Neo-
plastic invading cells must overcome the integrin-mediated
death (IMD) induced by the interaction of ITGB3 with the
extracellular matrix of host tissues to establish metastases
[25]. When a tumor cell migrates through a microenvironment
where the extracellular matrix (ECM) does not contain a suit-
able ligand for ITGB3, the integrin cytoplasmic tail recruits
caspase-8 to the cell membrane, and apoptosis is induced.
Stupack et al. [35] showed that ITGB3-expressing melanoma
cells undergo apoptosis in collagen gels that lack ITGB3 lig-
ands. ITGB3 speciﬁcally binds a wide range of ECM molecules,
including ﬁbronectin, ﬁbrinogen, von Willebrand factor, and
vitronectin [36]. The present proteomic analysis demonstrated
that several collagen-related genes were upregulated in LNM
tissues, while ﬁbronectin, ﬁbrinogen, and vitronectin were not
identiﬁed as upregulated proteins in LNM tissues (Fig. 2 and
Supplementary Table 3). Therefore, ITGB3 downregulation in
gastric cancer cells that showed LNM might reﬂect a survival
mechanism related to the prevention of IMD  in metastatic
tissues.
The problems of the proteomic biomarker studies are
lack of the validation studies in the independent clinical
samples from the multi-institutions. Selection of biomarker
candidates from the differentially expressed proteins and
acquisition of the independent clinical samples are criti-
cal steps in multi-institutional biomarker validation studies.
Transcriptome data are deposited in public databases with
clinicopathological data of the samples, and are freely avail-
able for independent validation studies; as clinical materials
are generally not very accessible, such infrastructure is highly
desirable for proteomic biomarker studies. However, presently,
there is no analogous proteomic database. For proteins whose
levels demonstrate concordance with mRNA  expression, a
transcriptome database should be a useful tool for biomarker
selection and validation. Several studies have compared
mRNA and protein levels in tissue culture cells. Chen et al. [37]
compared mRNA  and protein expression between two  gastric
cancer cell lines and estimated an overall correlation coefﬁ-
cient of 0.29. Previous studies comparing mRNA  and protein
expression in human and mouse cell lines concluded that the
mRNA levels explain approximately 40% of the variability in
protein levels [38]. Although these studies suggested possible
beneﬁts of using transcriptome databases for validation stud-
ies, the correlation between protein and mRNA  expression in
surgically resected tissues remain unclear. We  analyzed the
mRNA  levels for the 109 differentially expressed proteins by
using a public mRNA  expression database. Of these 109 pro-
teins, 67 were listed in the gastric cancer dataset of the GEO
database. We found that 26 of 67 genes (38.8%) showed a
concordant expression pattern for protein and mRNA.  These
concordant genes were enriched in GO terms related to
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Table 2 – Pathway enrichment analysis for the identiﬁed protein network consisting of 11 proteins.
Pathwaya Sourceb FDRc Number of
proteinsd
Included proteinse
Beta3 integrin cell surface interactions NCI-PID 1.00E−04 3 COL1A2, COL1A1, THBS1
Amoebiasis KEGG 1.11E−04 4 COL1A2, COL2A1, COL1A1, COL5A2
Integrin cell surface interactions Reactome 1.25E−04 4 COL1A2, COL2A1, COL1A1, THBS1
Protein digestion and absorption KEGG 1.43E−04 4  COL1A2, COL2A1, COL1A1, COL5A2
Signaling by PDGF Reactome 1.67E−04 5 COL1A2, COL2A1, COL1A1, THBS1, COL5A2
Integrin signaling pathway Panther 1.82E−04 4 COL1A2, COL2A1, COL1A1, COL5A2
Focal adhesion KEGG 2.00E−04 5 COL1A2, COL2A1, COL1A1, THBS1, COL5A2
Platelet adhesion to exposed collagen Reactome 2.50E−04 3 COL1A2, FCER1G, COL1A1
ECM-receptor interaction KEGG 3.33E−04 5 COL1A2, COL2A1, COL1A1, THBS1, COL5A2
Beta1 integrin cell surface interactions NCI-PID 5.00E−04 5 COL1A2, COL2A1, COL1A1, THBS1, COL5A2
Extracellular matrix organization Reactome 1.00E−03 7 PLOD2, MMP9, COL22A1, COL1A2, COL2A1,
COL1A1, COL5A2
Cell surface interactions at the vascular wall Reactome 1.31E−03 3 COL1A2, FCER1G, COL1A1
Axon guidance Reactome 1.42E−03 4 COL1A2, COL2A1, COL1A1, COL5A2
Platelet activation, signaling and aggregation Reactome 1.93E−03 4 COL1A2, FCER1G, COL1A1, THBS1
VEGFR3 signaling in lymphatic endothelium NCI-PID 4.00E−03 2 COL1A2, COL1A1
Syndecan-4-mediated signaling events NCI-PID 6.06E−03 2 MMP9, THBS1
Validated transcriptional targets of AP1 family
members Fra1 and Fra2
NCI-PID  7.76E−03 2 MMP9, COL1A2
Bladder cancer KEGG 9.39E−03 2 MMP9, THBS1
a Pathway enrichment analysis was performed using Cytoscape with Reactome FI plug-in [http://wiki.reactome.org/index.php/Reactome FI
Cytoscape Plugin].
b Reactome FI data set unites interactions from Reactome and those derived from other pathway databases, including KEGG, NCI-PID, BioCyc,
Panther and The Cancer Cell Map.
c FDR was calculated by Reactome FI plug-in, and the signiﬁcant threshold was set at less than 0.05.
F
g
D
zd The numbers of proteins which were examined in this study involved in
e Gene names which were identiﬁed to be signiﬁcantly up- or down-regula
ig. 5 – Functional characteristics of genes with concordant and 
rouped according to their protein and mRNA  expression pattern
AVID, version 6.7 (http://david.abcc.ncifcrf.gov). GO terms with 
-transformed and have been presented in a heatmap format. the pathway.
ted by proteomic experiment were shown.
discordant protein and mRNA  expression. Genes were
s and analyzed for enriched gene ontology terms by
enrichment of P < 0.20 were  listed, and P-values were
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Table 3 – List of 26 genes with correlation between protein and mRNA  expression.
Gene symbola Gene IDb Gene description Protein mRNA
Accession
numberc
Ratio
(T/NT)d
Ratio
(LNM/T)e
Probe IDf Accession
numberg
Ratio
(T/NT)d
Ratio
(LNM/T)e
Up-regulated genes at both protein and mRNA level
MMP9 4318 Matrix metalloproteinase-9 P14780 3.46 2.63 10805 T64837 2.56 1.03
AGMAT 79814 Agmatinase, mitochondrial Q9BSE5 2.91 2.51 15950 AA934764 1.11 1.24
CTSH 1512 Cathepsin H P09668  2.78 3.33 953 AA487231 1.04 1.05
TGOLN2 10618 Trans-Golgi network integral membrane protein 2 O43493 2.84 3.73 15417 T81338 1.21 1.05
SLC26A2 1836 Sulfate transporter P50443 2.42 2.07 10913 W15263 1.13 1.02
XRN2 22803 5′–3′ exoribonuclease 2 Q9H0D6 13.38 2.36 8162 AA028164 1.41 1.13
FAM103A1 83640 Protein FAM103A1 Q9BTL3 2.09 2.79 12871 AA432100 1.14 1.01
TAPBP 6892 Tapasin O15533 102.06 726.07 18291 AA704775 2.20 1.09
TCL1A 8115 T-cell leukemia/lymphoma protein 1A P56279 88.57 3.65 12786 R97095 1.07 2.62
GDAP1 54332 Ganglioside-induced differentiation-associated protein 1 Q8TB36 3.99 3.09 17310 H15302 1.45 1.06
NCF2 4688 Neutrophil cytosol factor 2 P19878 4.97 6.98 6201 AA872098 3.26 1.42
CHD4 1108 Chromodomain-helicase-DNA-binding protein 4 Q14839 2.07 2.49 5588 N34372 1.16 1.20
Down-regulated genes at both protein and mRNA level
CA2 760 Carbonic anhydrase 2 P00918 4.61E−01 2.99E−01 15331 H23187 1.21E−01 9.92E−01
GKN2 200504 Gastrokine-2 Q86XP6 3.76E−01 4.97E−01 8090 AI732254 1.45E−02 3.96E−01
MUC2 4583 Mucin-2 Q02817 4.04E−01 3.47E−01 25161 AA534503 4.62E−01 5.30E−01
CLDN18 51208 Claudin-18 P56856 3.91E−01 2.98E−01 11694 AI820565 3.45E−01 6.81E−01
DHRS4 10901 Dehydrogenase/reductase SDR family member 4 Q9BTZ2 4.87E−01 2.76E−01 18212 AA429946 6.46E−01 9.40E−01
DHRS3 9249 Short-chain dehydrogenase/reductase 3 O75911 3.98E−01 1.68E−01 1133 AA171606 7.77E−01 8.00E−01
HSD11B2 3291 Corticosteroid 11-beta-dehydrogenase isozyme 2 P80365 3.70E−01 3.27E−01 174 W95082 6.95E−01 8.90E−01
PGC 5225 Gastricsin P20142 4.34E−01 3.00E−01 19526 AI674972 3.04E−02 3.25E−01
REG4 83998 Regenerating islet-derived protein 4 Q9BYZ8 4.92E−01 4.95E−01 3562 AA535703 6.40E−01 7.55E−01
PRR15 222171 Protein PRR15 Q8IV56 4.33E−01 4.87E−01 17960 AA515032 8.49E−01 6.52E−01
GMPR 2766 GMP reductase 1 P36959 4.07E−01 3.27E−01 19 AA406242 5.21E−01 9.33E−01
CLMN 79789 Calmin Q96JQ2 2.91E−01 4.71E−01 23849 AA775028 7.31E−01 8.14E−01
ABCC3 8714 Canalicular multispeciﬁc organic anion transporter 2 O15438 4.72E−01 2.75E−01 15480 AA429895 7.51E−01 6.54E−01
a Gene symbols were derived from UniGene.
b Gene IDs were derived from Entrez Gene database.
c Accession numbers of proteins were derived from SWISS-PROT and NCBI nonredundant databases.
d Ratios were calculated by dividing the mean expression value of primary tumor samples (T) by that of non-tumor samples (NT).
e Ratios were calculated by dividing the mean expression value of lymph node metastasis samples (LNM) by that of primary tumor samples (T).
f Probe IDs were derived from NCBI GEO platform (GPL1283).
g Accession numbers of genes were derived from GenBank database.
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xidation reduction, or hormone metabolism, while the genes
ith discordant expression pattern were enriched in GO terms
elated to phagocytosis and cell adhesion. These results are
onsistent with the ﬁndings of Schwänhausser et al. [38],
ho  reported that genes related to oxidation reduction, and
etabolism were enriched in the group with stable and con-
ordant mRNA  and protein expression. They also found that
he GO terms of cell adhesion were enriched in the group of
enes that was characterized by stable mRNA  but unstable
rotein and was expected to have discordant expression [38].
nfortunately, the reliability of our analysis did not reach their
ne because the number of samples in our proteomic study
as limited and mRNA  expression data was obtained from
ifferent patient cohorts. Further investigation of additional
amples will be required to generalize our observations. The
se of public transcriptome databases will solve the problems
f proteomic biomarker studies, and therefore, these investi-
ations should be continued.
In our study, highly comprehensive and reproducible pro-
eomic analysis performed using a label-free quantiﬁcation
ethod showed downregulation of ITGB3 gene expression
n the LNM tissues. Downregulation of ITGB3 represents a
rosurvival response for overcoming apoptotic IMD at the
etastatic site. Further studies on the prognostic and biolog-
cal signiﬁcance of ITGB3 may lead to novel risk-stratiﬁcation
pproaches for gastric cancer.
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